1,1-Dimethylethyl N-[[8-(phenylmethyl)-8-azabicyclo[3.2.1]oct-3-yl]methyl]carbamate | 871727-13-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 1,1-Dimethylethyl N-[[8-(phenylmethyl)-8-azabicyclo[3.2.1]oct-3-yl]methyl]carbamate
• 英文别名: tert-butyl N-[(8-benzyl-8-azabicyclo[3.2.1]octan-3-yl)methyl]carbamate
• CAS: 871727-13-8
• 化学式: C₂₀H₃₀N₂O₂
• 分子量: 330.5
• InChiKey: AAWVOEWJHMNAJC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  24
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.65
• 拓扑面积：
  41.6
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• N-substituted nonaryl-heterocyclic NMDA/NR2B antagonists
  申请人：——

  公开号：US20020165241A1

  公开（公告）日：2002-11-07

  Compounds represented by Formula (I): 1 or pharmaceutically acceptable salts thereof, are effective as NMDA NR2B antagonists useful for relieving pain.

  由化学式（I）表示的化合物及其药学上可接受的盐，可作为NMDA NR2B拮抗剂，用于缓解疼痛。
• Nr2b receptor antagonists for the treatment or prevention of migraines
  申请人：——

  公开号：US20040204341A1

  公开（公告）日：2004-10-14

  The present invention encompasses a method for treating or preventing migraines in a mammalian patient in need of such treatment or prevention comprising administering to said patient an NR2B receptor antagonist in an amount that is effective to treat or prevent migraines. The invention also encompasses the combination of an NR2B antagonist with a cyclooxygenase-2 selective inhibitor, a calcitonin gene-related peptide receptor (CGRP) ligand, a leukotriene receptor antagonist or a 5HT 1B/1D agonist for the treatment or prevention of migraines.

  本发明涵盖了一种治疗或预防哺乳动物患者偏头痛的方法，包括向该患者施用有效治疗或预防偏头痛的NR2B受体拮抗剂。该发明还涵盖了将NR2B拮抗剂与环氧合酶2选择性抑制剂、降钙素基因相关肽受体（CGRP）配体、白三烯受体拮抗剂或5HT1B/1D激动剂结合使用，用于治疗或预防偏头痛。
• N-substituted nonaryl-heterocyclic nmda/nr2b antagonists
  申请人：——

  公开号：US20040209889A1

  公开（公告）日：2004-10-21

  Compounds represented by Formula (I): (I)or pharmaceutically acceptable salts thereof, are effective as NMDA NR2B antagonists useful for relieving pain. 1

  式(I)所代表的化合物或其药学上可接受的盐，作为NMDA NR2B拮抗剂，对缓解疼痛有效。
• Compounds for the treatment of inflammatory disorders and microbial diseases
  申请人：Siddiqui Arshad M.

  公开号：US20070167426A1

  公开（公告）日：2007-07-19

  This invention relates to compounds of the Formula (I): or a pharmaceutically acceptable salt, solvate or isomer thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, aggrecanase, ADMP, LpxC, ADAMs, TACE, TNF-α or combinations thereof.

  本发明涉及式(I)的化合物：或其药学上可接受的盐、溶剂或异构体，可用于治疗由MMPs、aggrecanase、ADMP、LpxC、ADAMs、TACE、TNF-α或其组合介导的疾病或病况。
• COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS
  申请人：Guo Zhuyan

  公开号：US20100145048A1

  公开（公告）日：2010-06-10

  This invention relates to compounds of the Formula (I): or a pharmaceutically acceptable salt, solvate or isomer thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, TNF-α or combinations thereof.

  本发明涉及公式(I)的化合物：或其药学上可接受的盐、溶剂化合物或异构体，可用于治疗由MMPs、ADAMs、TACE、TNF-α或其组合介导的疾病或病症。